Theriva Biologics Long Term Debt

Theriva Biologics (SYN) currently reports a long-term debt of $1.5M as of March 2026. That compares with $730K in the prior-year period — up 107.9% year over year. Use the charts on this page to explore Theriva Biologics's long-term debt history and peer comparisons.

Theriva Biologics's long-term debt increased from $730K to $1.5M — a 107.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Theriva Biologics reported $1.5M in long-term debt as of March 2026. That compares with $730K in the prior-year period — up 107.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Theriva Biologics, and consider following SYN for alerts when major investors trade the stock.

Theriva Biologics is classified in the Healthcare sector. On long-term debt, it currently shows $1.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SYN with unrelated industries.